 - Patients must not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the principal investigator PI; patients on greater than or equal to 2 anti-thrombotic agents, including but not limited to anti-platelet agents nonsteroidal anti-inflammatory drugs NSAIDSaspirin, clopidogrel, heparin, low molecular weight heparin, warfarin and a direct thrombin inhibitor will be excluded 